

*(To be printed on local headed paper)*

## **GP LETTER**

**Study title: A Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt's Lymphoma (BL) of International Prognostic Index (IPI) or High Intermediate Risk**

**Short title: R-CODOX-M/IVAC Trial**

**REC Reference: 05/Q0201/81**

**Version No: 6.0**

**Date: 23.06.2010**

Trial Number: RCM xxx

Dear Dr xxx

Your patient, \_\_\_\_\_ (date of birth dd/mm/yyyy), has newly diagnosed, poor prognosis diffuse large B cell lymphoma or Burkitts lymphoma. He/she has consented to participate in a study evaluating combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, methotrexate, etoposide and ifosfamide together with rituximab (an anti-CD20 monoclonal antibody) to see if this improves outcome for this disease.

Please find enclosed copy of the patient information sheets for this trial.

You will be kept up to date with your patient's progress but if you have any concerns or questions regarding this study please contact the responsible doctor:

Name:

Hospital:

Tel:

Kind regards